Claim Your Certificate
To claim your certificate, you must first complete an evaluation. To do this, click the “Get Started” or “Login” button. Please note, the button you see is dependent if you are currently logged in. Upon clicking this button, follow the cues to move through the evaluation and receive your certificate.
Course Overview
This educational initiative will enhance the understanding of the signs and symptoms of ATTR-CM that often overlap with other conditions leading to a misdiagnosis or delayed diagnosis and will focus on the diagnostic algorithm, including the appropriate use of Tc-99m PYP imaging, and the importance of image interpretation alongside other clinical findings. Understanding the central role of Tc-99m PYP imaging and the protocols for acquisition, processing and interpretation will be discussed to ensure understanding of the procedure and the data it provides. Finally, treatments used to manage and treat patients with ATTR-CM will be discussed.
Target Audience
This educational initiative will target general cardiologists, HF specialists and nurses, multimodality imagers, nuclear cardiologists, hematologists, neurologists, and primary care/internal medicine physicians. Trainees in cardiology and internal medicine will also benefit from a complete overview of amyloidosis.
Learning Objectives
After participating in this activity, learners should be able to achieve the following:
• Describe amyloidosis, including specific types, cardiac features, and disease burden
• Identify barriers to identification and diagnosis of patients suspected of ATTR
• Summarize the diagnostic evaluation for CA including multimodality imaging and laboratory testing
• Recognize patients at risk for hereditary ATTR (hATTR) and wild-type ATTR (wtATTR)
• Provide details of Tc-99m PYP including imaging protocol, semi-quantitative and quantitative scoring, interpretation including identifying false positive and false negative studies and components of an appropriate report
• Demonstrate understanding of current and emerging treatments for patients with ATTR-CM
Overall Goal
The overall goal of this educational initiative is to address, on a local level, the knowledge, competence and performance gaps in disease epidemiology, pathophysiology, diagnosis, and treatments for ATTR-CM. This initiative is designed to improve diagnosis across all patient populations, timely referral to amyloid experts, and knowledge of treatment options with the goal of improving outcomes of patients with ATTR-CM.
Continuing Education Term of Approval
Release Date: December 11. 2021
Expiration Date: March 11, 2022
After March 11, 2022, a fee will be charged to obtain your certificate.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Pfizer, Inc.
Medium and Software Requirements
Windows Requirements:
Operating system: Windows 10+
Browser: Chrome v90.0+, Firefox v84.0+, Edge v90.0+
Internet connection: DSL, cable modem, or other high-speed connection
Macintosh Requirements:
Operating system: Mac OS X 10.6.8+
Browser: Mozilla Firefox v84.0+, Safari 14+, Chrome v90.0+
Internet connection: DSL, cable modem, or other high-speed connection